Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response
about
BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking.Intravesical immunotherapy in nonmuscle invasive bladder cancerApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyEvolving immunotherapy strategies in urothelial cancerBacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineGenetic and immunological analysis of Mycobacterium tuberculosis fibronectin-binding proteinsPurification of a mycobacterial adhesin for fibronectin.Fibronectin facilitates Mycobacterium tuberculosis attachment to murine alveolar macrophages.Immunotherapy for bladder cancer.Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trialTh1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells.Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells.Role of urothelial cells in BCG immunotherapy for superficial bladder cancerMathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune responseBladder Cancer Immunotherapy: BCG and Beyond.Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder CancerAntiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.CLT1 targets bladder cancer through integrin α5β1 and CLIC3Role of neutrophils in BCG immunotherapy for bladder cancer.Immunotherapy for urothelial carcinoma: current status and perspectives.Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.Microbial-based therapy of cancer: current progress and future prospects.Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.Toll-like receptors in urothelial cells--targets for cancer immunotherapy.From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa.Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review.The mechanism of action of BCG therapy for bladder cancer--a current perspective.Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma.Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladderAnti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.The domains of human fibronectin mediating the binding of alpha antigen, the most immunopotent antigen of mycobacteria that induces protective immunity against mycobacterial infection.The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study.
P2860
Q24816183-D1C59D36-2A43-4388-8761-ABB1F54F21E1Q26775979-D98F0E03-C99D-4F24-BDE3-0D0A30DF3567Q26798372-2F1B7CA3-84E5-401D-BC2A-2CDC32AD75DEQ26823557-7CDCEBC0-75E2-4AE9-914B-093C693346C2Q27006765-8530E75E-264C-46BA-911D-B77073CDBE35Q33321358-434BB4B7-26AC-4C8E-ACA3-C0069388C6CAQ33595808-D42D06D8-D415-4C19-9E37-0FFC95A4ADA2Q34120576-F741019B-0F80-425B-A81A-022A737F0DD4Q34477444-D6566A97-5610-44D2-ADB3-91CBD43F034FQ34979760-215E52DD-B676-4097-BEE6-20ADFD6CF917Q35215350-D0D0C326-FAB2-4291-9FB6-BEA636922AC0Q35228328-A213B38F-7D16-4350-AEE6-E15BD474F6E9Q35748491-C5AF117F-6501-4CD2-BD6A-BA7E7F4A2D42Q35823499-9C7B6604-BCD2-46F7-B106-7C336906B8D8Q35842140-9EF75195-39FC-4B3E-8ED2-9093057FE8D7Q36038379-FBFE9BAC-9C55-475D-B0AB-3001CA1B4E21Q36072179-54DE26A4-F101-436A-827D-D179740034ECQ36142577-8D0B373A-2539-489C-AA66-157EC7E3C5FFQ36397311-830A0DD2-1FE5-4D3E-B29B-A4039F97FEAFQ36439816-011C8E65-A470-4CCC-84DD-770B151AF940Q36628548-480C0471-8E31-4C3B-BD8B-05AC241C0EF4Q36803793-48FA1A12-C62E-4E18-AAB4-E98FD89A6EB7Q37137381-1B02A8CA-F543-4BF4-A46E-8C30DB4EE698Q37317249-792E632F-3D9F-4D71-86D1-89D48B22E7A9Q37352975-806D29C6-B8C7-4222-92BE-7D49548ED27DQ37843621-FCDADA9C-49F0-48EB-BEFA-7B4669410765Q37894687-79042AA6-9353-4223-AE50-6D92861C1D52Q38131726-B003E644-8785-4174-AFAF-E99DCE1BEE3AQ38142595-2289D8EE-328B-4C49-8AF0-33BCE63A8F86Q38166720-98C97C96-33D0-4ED1-A927-B06A9BD57BADQ38184849-962A2EC2-1845-4E3E-AF6F-32F2F1F69D6DQ38232854-AF689F9D-2B05-42DD-89EB-5BD24846B4ACQ38684886-E38219F6-8CB6-450B-8010-2AF81E6D1973Q39200090-3025C3C0-0255-4BEC-99E3-75421FE25DA3Q39654910-2E241436-B0B5-4777-9A26-820C63EB53CEQ39702013-7EC6CFE1-A980-4808-8463-8B3380C957C8Q39755154-72210CB1-C177-47E5-A3A9-9D8EC9FB45E6Q42158453-2758FF0F-6E1C-495C-A883-69CCBF4A87C1Q43124669-8E54F5FA-FA78-400E-A41E-B1D88E6BE43A
P2860
Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response
description
1990 nî lūn-bûn
@nan
1990 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@ast
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@en
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@nl
type
label
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@ast
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@en
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@nl
prefLabel
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@ast
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@en
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@nl
P2093
P2860
P356
P1476
Fibronectin-mediated Calmette- ...... ssion of an antitumor response
@en
P2093
J K Ritchey
L R Kavoussi
T L Ratliff
P2860
P356
10.1172/JCI114434
P407
P577
1990-01-01T00:00:00Z